A Study of LY2624587 in Patients With Advanced Cancer
Study CXBA is a multicenter nonrandomized, dose escalation, open-label, Phase 1 study of intravenous LY2624587 in patients with advanced or metastatic cancer for which no treatment of higher priority exists.
Metastatic Cancer
DRUG: LY2624587
Recommended dose for Phase 2 studies, Baseline to study completion
Number of participants with clinically significant effects, Baseline to cycle 12|Radiological tumor measurement, Baseline, Cycle 1 Day-1, Cycle 2 - Day 1, Cycle 3 - Day 1|Pharmacokinetics of LY2624587, area under the concentration-time curve (AUC), Cycle 1 - Cycle 12|Pharmacodynamic, maximum peak concentration (Cmax)., Baseline to date last subject discontinues from study drug
Study CXBA is a multicenter nonrandomized, dose escalation, open-label, Phase 1 study of intravenous LY2624587 in patients with advanced or metastatic cancer for which no treatment of higher priority exists.